The Work We Fund

Funded projects
1,250+
Men's Health Partners
20
Countries
20
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Prostate Cancer Clinical Trials Consortium (PCCTC)

Movember Funding to Date

USD 1,250,000

What we seek to achieve

To design, implement and complete hypothesis-driven phase I and phase II trials in prostate cancer, translating scientific discoveries to improved standards of care.

Country
United States
Co-funded
Prostate Cancer Foundation and US Department of Defense Prostate Cancer Research Program (PCRP)
Implemented by
Prostate Cancer Foundation and Memorial-Sloan Kettering Cancer Center (MSKCC)
Project start date
2008
Project Status
Project Completed

About the project

The PCCTC is a clinical research organization consisting of a nationwide network of physicians at 13 academic institutions that offers simplified solutions for multicenter clinical trials.

PCCTC members collaborate to design, implement and complete hypothesis-driven phase I and phase II clinical trials in prostate cancer to rapidly bring scientific discoveries to men with prostate cancer.

The Consortium’s clinical trials focus on:
• Localized disease
• Rising PSA Non-Castrate disease
• Rising PSA Castrate disease
• Non-Castrate Metastatic disease
• Castrate Metastatic disease
• Biomarker discovery, validation

The PCCTC ensures that these centers maintain a robust infrastructure for conducting prostate cancer clinical trials. As part of the PCCTC, these institutions agreed to work in collaboration to rapidly and efficiently develop promising prostate cancer therapies.

The existence of the PCCTC is a powerful motivator for pharmaceutical companies to develop prostate cancer drugs, since it can help quickly advance clinical development of promising investigational medications.

The PCCTC also provides the pharmaceutical industry with scientific guidance on clinical trial design, helping to reduce the time needed to move a drug candidate from discovery to clinical investigation.

In a public-private partnership, the congressionally directed Medical Research Programs of the U.S. Department of Defense has joined PCF in funding the PCCTC. Memorial Sloan-Kettering Cancer Center, under the leadership of Dr. Howard I. Scher, serves as the Coordinating Center for the PCCTC.

>
Page 1 of 29